Press "Enter" to skip to content

Pfizer’s atopic dermatitis treatment meets goals in late-stage study

Abrocitinib, which belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, achieved statistically significant improvement in clearing the skin of patients as compared to placebo.

Original source: https://health.economictimes.indiatimes.com/news/pharma/pfizers-atopic-dermatitis-treatment-meets-goals-in-late-stage-study/69342913?utm_source=RSS&utm_medium=ETRSS